Literature DB >> 10522740

Opioid use in cancer pain. Is a more liberal approach enhancing toxicity?

P J Daeninck1, E Bruera.   

Abstract

The majority of cancer patients develop pain before death. This pain has been shown to be underdiagnosed and undertreated. Opioid use has increased in the past 20 years in both developing and developed countries. The changing pattern in opioid use has resulted in the emergence of neurotoxicity as a major side effect of the treatment of cancer pain. The syndrome of opioid-induced neurotoxicity (OIN) encompasses delirium, hallucinosis, myoclonus/seizures and hyperalgesia. Increased vigilance can lead to the timely diagnosis of OIN, and strategies for its treatment can be implemented with encouraging results. Identification and modification of risk factors for the development of OIN can help in its prevention and improve the quality of life in advanced cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10522740     DOI: 10.1034/j.1399-6576.1999.430910.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

1.  Frequency, Outcomes, and Associated Factors for Opioid-Induced Neurotoxicity in Patients with Advanced Cancer Receiving Opioids in Inpatient Palliative Care.

Authors:  Kyu-Hyoung Lim; Nhu-Nhu Nguyen; Yu Qian; Janet L Williams; Diane D Lui; Eduardo Bruera; Sriram Yennurajalingam
Journal:  J Palliat Med       Date:  2018-09-27       Impact factor: 2.947

Review 2.  Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.

Authors:  Shirley H Bush; Salmaan Kanji; José L Pereira; Daniel H J Davis; David C Currow; David Meagher; Kiran Rabheru; David Wright; Eduardo Bruera; Michael Hartwick; Pierre R Gagnon; Bruno Gagnon; William Breitbart; Laura Regnier; Peter G Lawlor
Journal:  J Pain Symptom Manage       Date:  2014-01-28       Impact factor: 3.612

3.  Addition of a second opioid may improve opioid response in cancer pain: preliminary data.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

4.  Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.

Authors:  Gabriela P Peirano; Guillermo P Mammana; Mariela S Bertolino; Tania Pastrana; Gloria F Vega; Jorgelina Russo; Gabriela Varela; Ernesto Vignaroli; Raúl Ruggiero; Arnaldo Armesto; Gabriela Camerano; Graciela Dran
Journal:  Support Care Cancer       Date:  2016-03-29       Impact factor: 3.603

5.  The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia.

Authors:  Shelley R Salpeter; Jacob S Buckley; Eduardo Bruera
Journal:  J Palliat Med       Date:  2013-04-04       Impact factor: 2.947

6.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Authors:  Tally M Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H Burns; Todd W Vanderah
Journal:  J Pain       Date:  2008-05-12       Impact factor: 5.820

Review 7.  Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin.

Authors:  Nicoleta Stoicea; Daric Russell; Greg Weidner; Michael Durda; Nicholas C Joseph; Jeffrey Yu; Sergio D Bergese
Journal:  Front Pharmacol       Date:  2015-05-27       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.